CA-MANSCAPED
Today, MANSCAPED™ , the global leader in men’s below-the-waist grooming, is cracking the code behind the company’s success with an exclusive introduction to its Founder and CEO, Paul Tran . From early beginnings to ongoing endeavors, Paul maintains a steadfast dedication to creativity, long-term thinking, and lifelong learning. These are just a few key takeaways as we get acquainted with the man leading MANSCAPED’s massive movement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005280/en/
A Born Entrepreneur. Born in Vietnam, Paul grew up with little, but with a big outlook on life. Although he experienced adversity at a young age, and as a first-generation immigrant in America who didn’t speak English, he reflects on his upbringing very fondly. Having nothing and coming from nothing ingrained a sense of ambition in Paul, driving him to make the most of any opportunity and practice empathy always.
After settling in New York, his vocabulary soon expanded beyond “hi” and, albeit the only Asian kid in school, he assimilated quickly among his peers and made friends due to his unassuming demeanor, self-awareness, and good nature. A born entrepreneur, Paul recalls one of his earliest memories from elementary school was when he hosted a raffle every Friday. It was a basic concept with no more than nickels on the table, but a weekly activity his classmates raved about and looked forward to. The popular game enhanced their lives unknowingly, while reaffirming Paul’s inner creative spirit.
Fast forward several years, this undeniable self-starter put himself through college at the University of Southern California where he studied at Marshall School of Business and Viterbi School of Engineering. He parlayed his education into his next ventures, which included launching and selling multiple businesses. One was a revolutionary science-backed skincare brand that provides a non-surgical solution for wrinkles and stretch marks. This was Paul’s first company that tackled taboos in the beauty space, but it most certainly wouldn’t be the last.
The MANSCAPED Movement. Paul launched MANSCAPED in 2016 with a vision of driving the movement that changes the face of men’s grooming. By focusing on the needs of what has, for too long, been a sensitive and often stigmatized subject, MANSCAPED has successfully untapped a vast market of male consumers. The brand not only provides premium tools and products for proper grooming but moves men forward by unlocking their confidence and allowing them to be the best versions of themselves. Paul lives by this mission every single day and envisions a world in the future where MANSCAPED plays a significant part in people’s lives all over the world.
Beyond seeing this vision materialize in real life, Paul thrives on working with his supportive and talented team. He is humble at his core, often highlighting teammates for execution and successes rather than taking any credit. This level of humility is understated but significant, as it flows deep into the organization. As CEO, Paul’s responsibilities are many. He loves overseeing the brand’s innovation and technology as a superior technician himself. He also spearheads the company’s direction as a brilliant strategist and constantly works to further establish MANSCAPED as an employer brand that puts company culture and people first. Ensuring that everyone feels valued, included, and appreciated for their efforts is extremely important to him.
Although at the helm of the entire MANSCAPED Family, Paul is a self-described introvert at heart and enjoys spending time in small groups where we can have meaningful conversations and directly care for his colleagues. His intelligent presentations, inspiring words, and witty humor are experienced by all 150 employees during MANSCAPED’s biweekly company-wide meetings. Calendar notifications go from mundane reminders to sparks of joy on these days. As a winner of Inc. Magazine ’s Best Workplaces in 2020, MANSCAPED is a workforce of individuals who are as happy as they are grateful for the environment Paul has created.
A Philanthropic Future. When he gets a sliver of time outside of MANSCAPED, Paul feeds his soul by spending time with his wife and two young children. This dedicated father and loving husband shares a special intellectual curiosity with his family. When their conversations run the gamut, Paul always walks away with a fresh perspective on life and appreciation for how far he has come. His deep-rooted desire to give back and commitment to social responsibility are fundamentals he has brought to MANSCAPED, as well as beliefs he lives by. Just one of his lifelong philanthropic goals is setting up his own foundation to help orphans and underprivileged children in Vietnam, which will be a full circle moment for him and so many others he’s impacted along the way.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target and Best Buy locations throughout the U.S., with further domestic and international retailers coming soon. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005280/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
